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Extra-medullary disease (EMD) in multiple myeloma
(MM) is associated with poor prognosis and resis-
tance to chemotherapy. However, molecular alter-
ations that lead to EMD have not been well defined.
We developed bone marrow (BM)- and EMD-prone
MM syngeneic cell lines; identified that epithelial-
to-mesenchymal transition (EMT) transcriptional
patterns were significantly enriched in both clones
compared to parental cells, together with higher
levels of CXCR4 protein; and demonstrated that
CXCR4 enhanced the acquisition of an EMT-like
phenotype in MM cells with a phenotypic conversion
for invasion, leading to higher bone metastasis and
EMD dissemination in vivo. In contrast, CXCR4
silencing led to inhibited tumor growth and reduced
survival. Ulocuplumab, a monoclonal anti-CXCR4
antibody, inhibited MM cell dissemination, sup-
ported by suppression of the CXCR4-driven EMT-
like phenotype. These results suggest that targeting
CXCR4 may act as a regulator of EMD through
EMT-like transcriptional modulation, thus represent-
ing a potential therapeutic strategy to prevent MM
disease progression.
INTRODUCTION
The process of tumor cell metastasis is a multilevel phenome-
non, which involves several steps including cell invasion, blood
vessel intravasation, and passage of the tumor cells into the cir-
culation, followed by homing or extravasation of the clonal cells622 Cell Reports 12, 622–635, July 28, 2015 ª2015 The Authorsinto distant tissues, resulting in the formation of new foci of tumor
colonization. Multiple myeloma (MM) represents a plasma cell
dyscrasia characterized by the presence of clonal plasma cells
within the bone marrow (BM), together with multiple myeloma-
tous ‘‘omas’’ throughout the skeleton. The occurrence of bone
lytic lesions suggests a continuous trafficking of tumor cells to
multiple BMareas. A subset ofMMpatientsmay present with ex-
tra-medullary disease (EMD), defined as an infiltrate of clonal
plasma cells at an anatomic site distant from the BM. EMD oc-
curs in about 4%–20% of patients with MM either at the time
of diagnosis or more frequently after multiple relapses (Oriol,
2011; Varettoni et al., 2010; Weinstock and Ghobrial, 2013). Prior
clinical observations have shown that patients with EMD have a
poor prognosis with a median overall survival of 1.3 years from
the time of diagnosis of EMD (Weinstock and Ghobrial, 2013).
A recent study has reported on the incidence and clinical fea-
tures of EMD in MM patients (Weinstock et al., 2015). However,
themechanisms by which EMD occurs in MM and whether it can
be therapeutically targeted to improve the survival of these pa-
tients remain poorly explored.
Epithelial-mesenchymal transition (EMT) programs occur in
both physiological conditions, such as during implantation,
embryogenesis, and organ development (type-1 EMT; Acloque
et al., 2009; Vicovac and Aplin, 1996) and in pathological set-
tings, including tissue regeneration and fibrosis (type-2 EMT;
Okada et al., 1997; Zeisberg et al., 2007a, 2007b) as well as can-
cer progression and metastasis (type-3 EMT; Ansieau et al.,
2008; Brabletz et al., 2001; Gupta et al., 2005; Hanahan and
Weinberg, 2000; Medici et al., 2008; Smit and Peeper, 2008;
Thiery, 2002; Yang et al., 2006; Yang and Weinberg, 2008). We
previously demonstrated that EMT-like transcriptional regulation
occurs in MM cells during hypoxic conditions (Azab et al.,
2012a). However, whether EMT plays a role in regulating MM
cell dissemination and EMD remains unexplored.
Among the factors that may modulate metastasis in the
context of solid tumors, CXCR4 and its ligand CXCL12 have
been reported to act as positive regulators of tumor cell metas-
tasis (Mu¨ller et al., 2001; Orimo et al., 2005; Schioppa et al.,
2003; Yagi et al., 2011). CXCL12 axis has been reported to
play a crucial role in facilitating BM homing and engraftment
of clonal MM plasma cells, thus resulting in enhanced MM cell
dissemination from bone-to-bone (Roccaro et al., 2014). Here,
we found that an EMT-like signature characterizes both EMD
as well as MM disease progression in a human MM cell line
propagated in vivo to develop EMD and BM-prone cells. Similar
results were observed in patient samples during disease pro-
gression with higher CXCR4 expression at the protein level
and a higher EMT-like signature at the transcriptional level.
We subsequently interrogated whether CXCR4 may enhance
a metastatic-prone phenotype in MM cells in vivo by favoring
EMT-like features within the tumor clone. We dissected the
in vivo functional relevance of CXCR4 in mediating the EMT-
related signature as well as MM cell dissemination, tumor
growth, and survival by using gain- and loss-of-function ap-
proaches. We next tested the anti-metastatic activity of the
monoclonal antibody anti-CXCR4 (ulocuplumab) in vivo, in the
context of both MM, confirming the ability of ulocuplumab to
modulate the expression of EMT-related genes. Overall, our
findings support the preclinical evidence for targeting CXCR4
as a novel approach to inhibit tumor cell metastasis through
the regulation of EMT.
RESULTS
EMT-like Transcriptional Regulation Characterizes
Extra-Medullary MM
To examine molecular alterations that occur in EMD, we gener-
ated EMD- and BM-prone MM cells by adopting a serial in vivo
selection approach (Figure S1A). After three rounds of in vivo se-
lections, the total number of humanMMcells engrafted to femur-
BM and liver was calculated for the BM-prone and EMD-prone
MM cell lines by counting GFP+ cells from the BM-harvested
cells and from the collagenase-digested liver, respectively.
Localization of the BM- and EMD-prone cells was examined us-
ing a fluorescencemicroscope on the whole transparent CUBIC-
treated mouse (Figure 1A). Specifically, both the BM- and the
EMD-clone colonized BM niches, including vertebrae, humeri,
tibiae, and femurs; in addition, the EMD-clone could metastasize
to and engraft within extra-medullary sites, including liver, kid-
ney, and abdominal-pelvic areas, whereas extra-medullary infil-
tration of the BM-prone clone was not detectable (Figure 1B). A
representative 3D reconstruction of BM and liver infiltration of
BM- and EMD/liver-prone MM cells is provided (Figure 1C).
The number of liver-infiltrating MM.1S cells was higher after
injection of the EMD-prone clone compared to the BM-prone
clone (Figures S1B and S1C). There were no significant differ-
ences in the number of BM-infiltrating cells between the EMD-
and BM-prone clones (Figure S1D), thus confirming that the
EMD-prone MM.1S clone presents with enhanced ability of liver
homing, together with an equivalent infiltrative ability within the
BM, compared to the BM-prone counterpart. In addition, the
two clones did not differ in terms of cell proliferation. Moreover,both the BM- and the EMD-prone clones significantly enhanced
their migration in response to the chemoattractant, with the
EMD-prone clone presenting with higher migration as compared
to the BM-prone clone (Figures S1E and S1F).
We next performed RNA sequencing on the BM- and EMD-
prone clones and compared their transcriptional profile to the
parental MM.1S cells. We found that the most significantly en-
richedmRNA signatures in EMD- and BM-prone clones included
genes defining an epithelial-mesenchymal transition (EMT),
genes upregulated in response to hypoxia, and genes related
to TNFa/NFkB response, as shown by GSEA (Figure 1D; Tables
S1 and S2). These findings, therefore, indicate that EMT occurs
in BM-disseminating MM cells but also in MM cells colonizing
EMD sites, such as the liver.
It is known that CXCR4 may act as a positive regulator of tu-
mor cell metastasis, and previous studies have shown that EMT
regulates CXCR4, leading to enhanced metastasis and cell
dissemination in solid tumors (Mu¨ller et al., 2001; Orimo et al.,
2005; Schioppa et al., 2003; Yagi et al., 2011). MM cells have
been previously shown to express CXCR4 and this has been
linked to the BM homing, engraftment, and growth of the clonal
plasma cells (Alsayed et al., 2007), and we have previously
shown that hypoxia may enhance CXCR4 expression in MM
(Azab et al., 2012a). We therefore hypothesized that CXCR4
may be upregulated with the acquisition of an EMT-like pheno-
type during disease progression and development of EMD in
MM, thus resulting in an enhanced MM cell dissemination. We
therefore evaluated the expression pattern of CXCR4 at the pro-
tein level and confirmed that both BM- and EMD-prone clones
expressed higher surface CXCR4 by flow cytometry, compared
to the parental cells, with a relatively higher expression in the
EMD-prone cells compared to the BM-prone cells (Figure S1G).
Importantly, these findings were recapitulated using patient-
derived EMD tissues, including brain, breast, liver, and abdom-
inal wall mass, where a positivity for CXCR4 was demonstrated
in CD138+ cell-infiltrated areas (Figure 1E). The expression
of other chemokine receptors was tested, showing minimal
differences between the BM- and the EMD-prone clones
(Figure S1H).
EMT-like Phenotype Acquisition in Patient Sampleswith
MM during Disease Progression
We next examined whether an EMT signature is also present in
patient BM-derived CD138+ cells. We therefore investigated
the publically available gene sets (GSE24080), classified patients
according to the International Staging System (ISS) (Greipp et al.,
2005), and confirmed a significant enrichment for EMT-related
mRNA signature in ISS1- versus ISS3-MM patients. Similarly,
an EMT-like phenotype was demonstrated, evaluating an inde-
pendent gene set (GSE6477) in active MM compared to smol-
dering MM patients, as well as in relapsed MM patients (Figures
2A and 2B). To further investigate whether CXCR4 may favor
the acquisition of an EMT-like signature in MM cells, we catego-
rized primary BM-MM-derived CD138 cells according to their
CXCR4 expression levels. Patients with higher (log fold
change > 1.1) and lower CXCR4 expression (log FC < 1) were
next examined (Figure S2A). We first adopted a positive control
gene set, represented by a signature of genes activated byCell Reports 12, 622–635, July 28, 2015 ª2015 The Authors 623
Figure 1. RNA Sequencing Shows Enrichment for Epithelial-to-Mesenchymal Transition Signature in Bone-Marrow- and Liver-Prone
MM Cells
(A and B) BM-prone and liver-prone MM.1S/GFP+ cell lines were developed by serial in vivo selection as described within Figure S1. BM- and liver-prone clones
were injected i.v. into SCID/Bg mice (n = 3/group). Visualization of BM- and liver-colonizing MM cells was documented by fluorescence microscopy using
transparent CUBIC-treated whole-mouse body.
(legend continued on next page)
624 Cell Reports 12, 622–635, July 28, 2015 ª2015 The Authors
Figure 2. EMT Characterizes MM Patients
with Advance Stage Disease
(A) MM patients (GSE24080) with ISS3 presented
with an enrichment for EMT-like mRNA signature,
compared to MM patients with ISS3, as shown by
GSEA.
(B) MM patients (GSE6477) with active MM pre-
sented with an enrichment for EMT-like mRNA
signature, compared to patients with smoldering
MM. Similarly, an enrichment for EMT-like mRNA
signature was observed in relapsed MM patients,
as shown by GSEA.CXCR4 (CXCR4_OE; instance ID OEB005_HT29_96H:
BRDN0000410050) and confirmed an enrichment of the
CXCR4_OE signature in patients characterized by higher
CXCR4 expression versus patients with lower CXCR4 expres-
sion, as shown by using GSEA (FDR 0.1; p = 0.01; Figure S2B).
We further proceeded to identify the pathways differentially
expressed between BM-MM CD138+ plasma cells with high
CXCR4 expression (MM-CXCR4high), compared to clonal MM
plasma cells with lower CXCR4 expression (MM-CXCR4low), by
using GSEA and observed an EMT-related pathway to be signif-
icantly enriched in MM- CXCR4high versus MM-CXCR4low (FDR
0.026; p = 0.01; Table S3). These findings further suggest that
CXCR4 may possibly modulate EMT in the context of MM.(C) GFP-expressing BM- and EMD-prone MM1.S cells were visualized within the resected BM and liver, re
and liver and reconstructed in 3D using z stack images. GFP expression (green signal) indicates myeloma
conjugated Lycopersicon Esculentum Lectin (red signal).
(D) BM- and liver-prone MM.1S cells were subjected to RNA sequencing, showing an enrichment for EMT
GSEA. The green curves show the enrichment score and reflect the degree to which each gene (black verti
ranked gene list. The heatmap indicates the relative abundance (red to blue) of the genes specifically enriched
to original MM.1S cells. EMT gene sets were enriched in the BM- and in the liver-prone MM.1S cells.
(E) Expression of CXCR4 on samples obtained from patients with extra-medullary MM, including brain, breas
immunohistochemistry using anti-CXCR4 antibody. Staining for CD138 was also performed to identify the MM
EMD tissues stained for CXCR4 and CD138. Immunohistochemistry images were obtained from brain, breas
with an Eclipse 80i microscope (Nikon); 203 magnifications are provided.
Cell Reports 12, 622–CXCR4Regulates the Acquisition of
an EMT-like Phenotype in MM
To date, several studies have shown that
EMT leads to CXCR4 upregulation, lead-
ing to enhanced tumor cell dissemination
(Jung et al., 2013; Mu¨ller et al., 2001).
However, we sought to examine whether,
conversely, CXCR4 may regulate the
EMT-like transcriptional regulation in MM
using in vivo models. We first performed
CXCR4 gain-of-function studies and
confirmed that CXCR4 overexpression
led to the acquisition of a mesenchymal-
like morphology, with changes in actin
cytoskeleton reorganization of MM cells
with protrusion of cell pseudopodia,
compared to empty vector (EV)-infected
cells (Figure 3A). This phenotype was
also supported by the modulation of
EMT-related markers in CXCR4-overex-pressing (CXCR4/OE) MM.1S cells compared to EV-infected
cells, as shownby upregulation of Slug, Snail, andTwist, together
with downregulation of E-cadherin (Figure 3B). Of note, CXCR4/
OE cells also showed enhanced activation of pro-survival path-
ways, such as p-ERK and p-AKT, together with modulation of
migration and adhesion-related proteins (Figure 3B). In addition,
CXCR4/OE MM cells presented with enhanced invasive proper-
ties compared to control cells (Figure 3C). Demonstration of
CXCR4 overexpression in CXCR4/OE MM cells compared to
EV-infected cells was performed using qRT-PCR and western
blot (Figures 3B and S3A). Similarly, additional MM cell lines
(RPMI.8226) presented with the same changes in cellular
morphology, together with enhanced Slug, Snail, and Twistspectively, using transparent CUBIC-treated femur
cells; blood vessels were labeled with DyLight 594
-related mRNA signature, as shown by performing
cal lines) is represented at the top or bottom of the
in the BM- or liver-proneMM.1S cells as compared
t, liver, and abdominal wall mass, was evaluated by
-infiltrating areas. Isotype control was used for the
t, liver, and abdominal wall. Tissues were visualized
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Figure 3. CXCR4 Mediates Acquisition of EMT-like Features in MM Cells In Vitro and In Vivo
(A) CXCR4-overexpressing MM.1S cells (MM.1S CXCR4+) present with an EMT-like phenotype compared to empty vector (EV)-infected cells used as control, as
shown by confocal microscopy. Anti-actin Ab and DAPI were used to stain cytoplasm and nuclei, respectively. (403 and 1003 magnifications are provided).
(B) Protein cell lysates were obtained fromCXCR4+MM.1S cells present with modulation of EMT-related proteins, together with upregulation of pro-survival- and
migration/adhesion-related proteins compared to EV-infected cells used as control.
(C) CXCR4+ MM.1S cells display enhanced invasive properties compared to EV-infected cells used as control. Error bars indicate SD.
(legend continued on next page)
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Figure 4. CXCR4 Overexpression Enhances
MM Cell Ability to Disseminate to Medullary
and Extra-Medullary Sites
(A) Schematic diagram of SCID-murine experi-
ment. Four mice for each group were used.
CXCR4-overexpressing (CXCR4/OE) MM cells
carrying BFP and EV-transfected cells carrying
RFP were used.
(B) Flow-cytometry analysis of the injected cell
mixtures, showing equal distribution between the
CXCR4/OE and the EV cells. CXCR4 expression of
the cell populations was analyzed by gating BFP+
or RFP+ fractions.
(C) Number of CXCR4/OE and EV MM cells that
colonized the host bone and the liver was quanti-
fied by flow cytometry. Error bars indicate SD.upregulation and E-cadherin downregulation, when CXCR4 was
overexpressed (Figures S3B and S3C).
CXCR4 Leads to Enhanced In Vivo Dissemination and
Development of EMD
We first used an in vivo xenograft model of MM cell dissemina-
tion (Roccaro et al., 2014): MM cells, either CXCR4/OE or EV-in-
fected (control), were loaded into femurs and implanted subcu-
taneously into recipient mice. CXCR4/OE cells presented with a
higher ability to metastasize from bone to bone compared to
control cells, as confirmed by using both immunohistochemistry
and quantification by flow cytometry in harvested host femurs
(Figures 3D and S4A). CXCR4 overexpression was confirmed
ex vivo on cells harvested from the host femur. Importantly,
lower expression of human (h)-E-cadherin, together with higher
mRNA expression of h-Twist, h-Snail, and h-Slug, was
confirmed within the BM of the host femur (Figure 3E). Taken(D) Bone chips were loaded with either CXCR4+ MM.1S or EV-infected MM.1S and implanted subcutaneou
host femur was harvested and used for immunohistochemistry using anti-human CD138 for detecting meta
(E) Higher mRNA levels of CXCR4, Twist, Snail, and Slug, together with lower mRNA levels of E-cadherin,
femurs of mice implanted with CXCR4+-loaded femurs compared to those where EV-infected cells were us
p indicates p value. Average of experiments performed in triplicate is shown.
Cell Reports 12, 622–together, these observations further
confirm that CXCR4 upregulates EMT-
like transcription factors, leading to
enhanced cell dissemination in vivo.
We further investigated whether
CXCR4 can enhance EMD development
by performing an in vivo competition
assay: MM cells, either blue fluorescent
protein (BFP)+/CXCR4/OE or red fluores-
cent protein (RFP)+/EV infected (control),
were mixed in equal numbers and inocu-
lated in syngeneic femurs that were trans-
planted unilaterally in the dorsum of
mice (Figures 4A and 4B). We observed
a significantly higher dissemination of
CXCR4/OE MM cells to the liver tissue
(EMD) compared to EV-infected MM cells
used as control (Figure 4C), indicating astrong propensity of CXCR4/OE cells to disseminate to the liver,
thus leading to EMD.
CXCR4 Silencing Leads to Reduced MM BM Homing,
Tumor Growth, and Enhanced Survival
To corroborate the functional relevance of CXCR4 in supporting
MM cell dissemination, CXCR4 loss-of-function studies were
performed (Figure 5A). CXCR4 knockdown led to significant inhi-
bition of MM cell homing to the BM, as shown by using intravital
confocal microscopy (Figure 5B), together with inhibited MM tu-
mor growth in vivo, as shown by using bioluminescence imaging
(Figures 5C and 5D). Importantly, prolonged survival was docu-
mented in mice injected with CXCR4-silenced MM cells
compared to control mice injected with scramble probe-infected
MMcells (Figure 5E). Confirmation of CXCR4 k.d. was performed
ex vivo by using qRT-PCR on BM cells obtained from harvested
femurs (Figure 5F).sly into SCID/Bg-recipient mice (n = 5/group). One
stasized MM.1S cells.
were observed in BM cells obtained from the host
ed. Error bars indicate SD.
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Figure 5. CXCR4-Silenced MM Cells Present with Reduced Homing, Tumor Growth In Vivo and Improved Survival
(A) Validation of CXCR silencing at protein level by western blot on CXCR4 K.D. MM cells as compared to scramble cells.
(B)CXCR4silencing inMMcells led to inhibitedMMcell homing to the bonemarrow, as shownby using intravital confocalmicroscopy (day 34;GFP+MMcells, green
color; EvansBluepositive-bloodvessels, red color). High-resolution imageswith cellulardetail wereobtained through the intactmouseskull at depthsof up to250mm
fromthesurfaceof the skullusinga1030.45NAPlan-Apoobjective (CarlZeiss)andassembled together togenerateafinal image thatdepicts thewholebonemarrow.
(C and D) SCID/Bg mice were injected with either CXCR4-silenced MM cells or scramble probe-infected cells (n = 7/group). Detection of tumor growth was
performed by measuring bioluminescence imaging (BLI) intensity at different time points post-MM cell injection (days: 7; 14; 35; 39; and 42). CXCR4 silencing in
MM cells led to inhibited MM tumor growth in vivo.
(legend continued on next page)
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Figure 6. Ulocuplumab Inhibits the EMT
Phenotype Acquisition in MM Cells Both
In Vitro and In Vivo
(A and B) MM.1S cells were cultured in presence
or absence of ulocuplumab (0.025–1 mM; 6 hr).
MM.1S cells were then harvested, and cell lysates
were subjected to western blot using anti-
p-b-catenin, -b-catenin, -p-GSK3-b, -tubulin, -Snail,
-Twist, -Slug, and -E-cadherin antibodies. Adjusted
band intensity for each protein normalized to the
relative loading control is provided within Figures
S5A and S5B and expressed as fold of control
(control corresponds to untreated cells).
(C and D) Bone chips from donor mice were
loaded with CXCR4+ MM.1S and implanted sub-
cutaneously into SCID/Bg-recipient mice. Mice
were treated with either control Ab or ulocuplumab
(n = 5/group; 10 mg/kg; i.p.; 43 to 53/week).
Ulocuplumab led to inhibited MM cell growth
within the implanted bone (implanted bone is
shown in C), together with inhibited ability of MM
cells to metastatize from bone to bone (host bone
is shown in D).
(E) The ability of ulocuplumab to modulate EMT
was demonstrated ex vivo: decreased mRNA
levels of Twist, Snail, and Slug, together with
increased mRNA levels of E-cadherin, were
observed in BM cells obtained from the host fe-
murs of ulocuplumab-treated mice. No MM cell-
injected mice were used as control. p indicates p
value. Average of experiments performed in tripli-
cate is shown. Error bars indicate SD.CXCR4 Inhibition by a Selective Monoclonal Antibody,
Ulocuplumab, Leads to ReducedMMCell Dissemination
Supported by EMT Inhibition
We further confirmed that CXCR4 is a critical regulator of EMT
activation by evaluating the effects of the selective monoclonal
antibody anti-CXCR4 (ulocuplumab) on the modulation of tumor(E) Kaplan-Meier curve showing prolonged survival in CXCR4 K.D. cell-injected mice versus scramble probe
(log rank test).
(F) Detection of human CXCR4 level has been performed by qRT-PCR (DDCt method) on cells isolated ex vivo
Error bars indicate SD.
Bars indicate SD. p indicates p value.
Cell Reports 12, 622–cell dissemination and EMT, using clini-
cally achievable concentrations (Kuhne
et al., 2013). MM cells were exposed to
increasing concentrations of the anti-
CXCR4 monoclonal antibody, ulocuplu-
mab. Ulocuplumab led to the regulation
of EMT transcription factors including
Snail, Twist, Slug, andE-cadherin (Figures
6A and S5A). Ulocuplumab also led to up-
regulation of p-GSK3b and p-b-catenin,
responsible for b-catenin degradation
(Figures 6B and S5B). b-catenin is consid-
ered amarker of EMT in the context of em-
bryonic development, fibrosis, and tumor
progression (Brabletz et al., 1998; Kalluriand Neilson, 2003; Medici et al., 2006) and has been shown to
modulate gene expression related to EMT, such as Snail. Our
findings therefore suggest a possible role of CXCR4 in mediating
acquisition of the EMT phenotype through b-catenin modulation.
To further investigate whether CXCR4 blockade may lead to
an inhibition of MM cell dissemination to BM niches, we testedcell-injected mice (n = 7/group). p indicates p value
from the bone marrow femurs. p indicates p value.
635, July 28, 2015 ª2015 The Authors 629
Figure 7. Ulocuplumab Exerts Anti-MM
Activity, Either as Single Agent or in Combi-
natory Regimens In Vivo, and Induces
Toxicity on Primary MM Cells
(A) SCID/Bg mice were injected with 5 3 106
MM.1S-GFP+/Luc+ cells i.v. and treated with ulo-
cuplumab (10 mg/kg; 33 to 43/week; i.p.) or iso-
type control antibody (30 mg/kg; 33 to 43/week;
i.p.). Ulocuplumab led to inhibited MM cell homing
to the BM, as shown by using intravital confocal
microscopy at the 3rd week. (GFP+MM cells, green
color; Evans-Blue-positive blood vessels, red
color). High-resolution images with cellular detail
were obtained through the intact mouse skull at
depths of up to 250 mm from the surface of the skull
using a 103 0.45NA Plan-Apo objective (Carl
Zeiss) and assembled together to generate a final
image that depicts the whole bone marrow.
(B) SCID mice were implanted with RPMI-8226,
MM.1S cells and treated with ulocuplumab
(10 mg/kg; 33 to 43/week; i.p.), isotype control
antibody (30 mg/kg; 33 to 43/week; i.p.), or lenali-
domidealone (50mg/kg;daily; i.p.) or incombination
with ulocuplumab, starting 8 days post-implantation
(n = 8/group). Similarly, SCID mice were implanted
with OPM-2 cells s.q. and treated with ulocuplumab
(10 mg/kg; 33 to 43/week; i.p.), isotype control
antibody (30 mg/kg; 33 to 43/week; i.p.), borte-
zomib alone (0.8 mg/kg; 23/week), or in combina-
tion with ulocuplumab, starting 14 days post-
implantation.
(C) BM-derived primary CD138+ cells were
cultured in presence or absence of ulocuplumab
(50–400 nM; 48 hr). Cell toxicity was performed by
using MTT. Ulocuplumab exerted anti-MM activity
against primary MM cells. Error bars indicate SD.the effect of ulocuplumab on tumor dissemination in vivo, using
clinically achievable concentrations (Kuhne et al., 2013). Ulocu-
plumab exerted an anti-MM activity in situ, within the s.q. im-
planted bones (Figure 6C), and also reduced MM cell dissemi-
nation/metastasis from the implanted bone to the host bone
(Figures 6D and S6A). We next examined whether ulocuplumab
modulated EMT-related gene expression in the MM cells
metastasized to the host bones. We found that higher mRNA
expression of h-E-cadherin, together with reduced mRNA
expression of h-Twist, h-Snail, and h-Slug was found in BM
cells harvested from the host bones of mice treated with ulocu-
plumab. These results confirm that the reduced MM cell
dissemination to the host bone is a result of the combinatory ef-
fect of ulocuplumab-dependent modulation of EMT in addition630 Cell Reports 12, 622–635, July 28, 2015 ª2015 The Authorsto ulocuplumab-dependent modulation
of tumor growth within the primary im-
planted bone. Non-MM-harboring mice
were used as controls (Figure 6E).
To further demonstrate that CXCR4 in-
hibition may lead to inhibited MM cell
homing to the BM, ulocuplumab was
tested in vivo. MM.1S GFP+/Luc+ cells
were injected i.v. into SCID/Bg mice and
treated with either control Ab or ulocuplu-mab. Ulocuplumab-treated mice presented with reduced BM
homing, as shown by intravital confocal microscopy (Figure 7A).
In addition, using s.q. xenograft models, mice were treated with
control Ab or ulocuplumab: in all the three models in which three
different MM cell lines were used, ulocuplumab showed signif-
icant anti-MM activity compared to control Ab-treated mice. In
addition to the anti-MM effect of ulocuplumab used as single
agent, a more-significant MM tumor growth inhibition was
observed in vivo when ulocuplumab was used in combinatory
regimens with lenalidomide and bortezomib (Figure 7B). We
next validated the effect of ulocuplumab on targeting patient
BM-derived MM cells, showing induction of toxicity on primary
MM cells exposed to increasing doses of ulocuplumab (Fig-
ure 7C). The observed ulocuplumab-mediated anti-MM activity
in vivo was also supported by the demonstration of ulocuplu-
mab-dependent inhibition of MM cell proliferation in the context
of primary BM mesenchymal stromal (BM-MSC) cells, in vitro
(Figure S7A). We further corroborated these findings at protein
levels: primary MM BM-MSCs were cultured in the presence
of MM cells exposed to increasing concentrations of ulocuplu-
mab. We demonstrated that ulocuplumab inhibited the BM-
MSC-dependent upregulation of p-ERK, p-Akt, and p-Src in
MM cells (Figure S7B). Importantly, possible mechanisms of
ulocuplumab-induced MM cell apoptosis were studied,
showing the ability of ulocuplumab to target MM cells in a cas-
pase-dependent manner, as demonstrated by induced cleav-
age of both caspase-9 and PARP (Figure S7C).
DISCUSSION
CXCR4 has been considered a hallmark regulator of tumor
metastasis as demonstrated both in solid tumors (Mu¨ller
et al., 2001) and in hematological malignancies such as MM
(Azab et al., 2012a; Mo¨ller et al., 2003), AML (Brault et al.,
2014; Burger et al., 2003), and ALL (Juarez et al., 2009). How-
ever, none of these studies have previously implicated CXCR4
in the promotion of MM growth to EMD sites. The presence of
multiple lytic lesions is one of the main clinical features of pa-
tients with active MM, thus suggesting the ability of clonal
plasma cells to disseminate from bone to bone (Ghobrial,
2012; Kyle and Rajkumar, 2008). The BM-homing process of
MM cells has been shown to be supported by the activation
of the CXCR4/CXCL12 axis (Alsayed et al., 2007; Roccaro
et al., 2014). Recent evidence supports that CXCL12 is essen-
tial in favoring a pro-metastatic BM niche in MM, as well as in
bone metastatic solid tumors, including lung, gastric, medullary
thyroid, renal, and prostate carcinomas (Roccaro et al., 2014).
Type 3 epithelial-to-mesenchymal transition (EMT) represents
one of the main features of metastatic solid tumor cells, where
malignant epithelial cells display the ability to leave the primary
tumor nodule, migrate to distant tissue sites, and create a sec-
ondary metastatic tumor nodule (Kalluri and Weinberg, 2009;
Yang and Weinberg, 2008). In a small fraction of MM patients,
plasma cells are capable of infiltrating EMD sites including liver,
CNS, lungs/pleural fluid, and subcutaneous areas (Weinstock
and Ghobrial, 2013). These patients are usually refractory to
therapeutic agents and have a poor prognosis. This indicates
that there is an urgent need for understanding the molecular
mechanisms responsible for MM cell dissemination to EMD
sites, thus potentially allowing for the development of better
therapeutic modalities that target this unique subset of
patients.
Previous observations have demonstrated that induction of
the EMT phenotype leads to enhanced CXCR4 expression in
epithelial tumors (Jung et al., 2013; Mu¨ller et al., 2001). However,
no prior studies have shown that EMT may occur in hematologic
malignancies, such as MM, and that CXCR4 can possibly modu-
late the acquisition of an EMT-like phenotype in the context
of MM.
Here, we have generated BM- and EMD (liver)-prone MM
clones by serial in vivo selection using MM xenograft mouse
models, defined a significant EMT-related mRNA signature inboth clones as compared to the parental MM cells, and
confirmed the presence of CXCR4 at protein level in both the
BM- and the EMD-prone clones. Importantly, an EMT mRNA
signature was significantly enriched in MM patients with
advanced disease, according to ISS (Greipp et al., 2005). By
interrogating whether the CXCR4 levels may affect the EMT
signature, we stratified primary BM-derived plasma cells ob-
tained from MM patients according to their CXCR4 expression
and found that patient-derived plasma cells with high CXCR4
expression present with significant enrichment of EMT-related
pathways compared to those obtained from patients with low
CXCR4 expression, thus suggesting a potential role for CXCR4
in facilitating the acquisition of an EMT phenotype in MM. We
therefore interrogated whether CXCR4 may favor the ability of
MM cells to disseminate from bone to bone or to extra-medullary
sites, such as the liver, by modulating their EMT phenotype,
independently from the functional role of the CXCR4/CXCL12
axis. Our findings show that CXCR4 gain of function exerts a
pro-EMT-like phenotype in MM cells, with a higher degree of
cellular invasion and metastasis, as shown both in vivo and
in vitro, leading to MM disease progression. Importantly, the
presence of an EMT signature was also defined and confirmed
at the transcriptome level in liver-metastasizing MM clones. In
contrast, CXCR4-silenced MM cells presented with reduced tu-
mor growth in vivo together with enhanced survival. Importantly,
the novel monoclonal anti-CXCR4 antibody exerted a dual effect
against MM cells, as shown by inhibition of EMT both in vivo and
in vitro, supported by reduced cell survival and induced cell
apoptosis. Therefore, our data support the activity of CXCR4 in-
hibitors such as ulocuplumab in regulating tumor cell dissemina-
tion and metastasis through the inhibition of EMT transcriptional
regulation.
A previous study had shown that bortezomib-resistant murine
cell lines show reduced expression level of CXCR4 compared to
the bortezomib-sensitive counterpart (Stessman et al., 2013),
and this predicted poor survival in MM patients treated with
the proteasome inhibitor. The bortezomib-resistant murine MM
subclones may present with different genomic aberrations or
changes at transcriptome level, compared to the bortezomib-
sensitive murineMM subclones, and that may explain the results
in this report. However, recent clinical studies do not support an
increase in the incidence of EMD development post-bortezomib
therapy (Weinstock et al., 2015). Therefore, we hypothesize that
specific MM cell subclones may have differences in CXCR4
expression; it could also be postulated that a small subclone
within the BM that has specific mutations or copy number alter-
ations is more ‘‘fit’’ and capable of metastasis with specific
tropism to EMD sites. Alternatively, subclones that disseminate
to the BM or to EMD sites may upregulate CXCR4 by epigenetic
alterations or hypoxia-driven upregulation of CXCR4 to allow for
the proliferation and survival of these cells in a new host environ-
ment. Further studies are, therefore, necessary to define these
potential mechanisms that lead to upregulation of CXCR4.
Taken together, these studies indicate that EMD development
and cell dissemination and metastasis in MM is regulated by
an upregulation of EMT-like transcriptional activity that leads
to higher CXCR4 expression. Moreover, specific inhibition of
CXCR4 by a monoclonal antibody can serve as a therapeuticCell Reports 12, 622–635, July 28, 2015 ª2015 The Authors 631
target of EMT activation and inhibition of tumor dissemination in
MM specifically in EMD.
EXPERIMENTAL PROCEDURES
Cells
Primary BM-MSCs were obtained from MM patients. BM mononuclear cells
were isolated using Ficoll gradient centrifugation. Primary plasma cells were
isolated using microbead (CD138)-positive selection. The remaining popula-
tion (CD138 negative) was cultured and selected in plastic flasks and used
at the third to fourth passage. Following with previous reports and International
Society for Cellular Therapy recommendations (Dominici et al., 2006; Garayoa
et al., 2009; Roccaro et al., 2013), BM-MSCs were devoid of hematopoietic
cells (CD34, CD138, CD45, and CD14) and positive for the remaining
markers (CD73+, CD90+, CD105+, and CD106+), indicating their multipotent
mesenchymal stromal cell phenotype. Approval for these studies was ob-
tained from the Dana-Farber Cancer Institute Institutional Review Board.
Informed consent was obtained from all patients and healthy volunteers in
accordance with the Declaration of Helsinki protocol. The luciferase (luc)-ex-
pressing MM.1S-GFP/luc cell lines were generated by retroviral transduction
with the pGC-gfp/luc vector (kind gift of Dr. A. Kung, Dana-Farber Cancer Insti-
tute). MM.1S, RPMI.8226, and IM9 cell lines were purchased from ATCC;
OPM2 cells were purchased from DMSZ. Primary MM-BM-derived CD138+
cells were purified using CD138-microbeads (Miltenyi Biotech).
Development of BM- and EMD-Prone MM Clones
BM-prone and EMD-prone MM cell lines were developed by serial in vivo se-
lection. A schematic representation of the experimental procedure is provided
in Figure S1. Briefly, a total of 5 3 106 GFP+MM.1S cells were injected into
mice by intravenous injection. After hind-limb paralysis development, MMcells
were harvested from either BM or liver from euthanized mice. To harvest BM
engrafted MM cells, femurs and tibias were resected and BM mononuclear
cells were collected. To harvest liver engrafted human MM cells, whole liver
was resected under sterile conditions. The resected livers were minced with
sterile razor blades and placed in RPMI 1640 media supplemented with colla-
genase/Dispase/DNase I enzyme mixture (Roche Diagnostics). Samples were
incubated at 37C for 1 hr with gentle shaking. After enzyme digestion, cells
were washed three times with RPMI 1640 media and underwent Ficoll density
gradient centrifugation to remove dead cells and debris. Total number of hu-
manMMcells was calculated by counting GFP+ cells under an epi-fluorescent
microscope using hemocytometer. Cells were resuspended in culture medium
and allowed to grow. GFP+ cells were sorted for further propagation in culture
or for inoculation into new mice. After the first in vivo selection, MM cells har-
vested fromdifferent micewere pooled, and the resulting cell populationswere
subjected to the second round and third rounds of in vivo selection.
Fluorescent Imaging on Transparentized Mice
Mice injected with BM-prone or EMD-prone myeloma cells were observed for
their tumor localization after transparentizing the mice using ‘‘clear, unob-
structed brain imaging cocktails and computational analysis’’ (CUBIC) reagent
as previously described (Susaki et al., 2014). Briefly, mice were injected with
0.1ml of 1mg/ml DyLight594-labeled Lycopersicon Esculentum Lectin (Vector
Laboratories) for blood vessel staining. After anesthesia with isoflurane, the
mice were transcardially perfused with PBS, 4% (w/v) paraformaldehyde,
and CUBIC-1 reagent via heart left ventricle. Mice were subsequently
immersed in CUBIC-1 reagent for 5 days and further immersed in CUBIC-2 re-
agent for additional 5 days. Lower magnification images were obtained using
an OV100 whole-mouse imaging system (Olympus). Images were acquired
with 0.133, 0.273, and 0.563 objective lenses. All data were taken with a
monochrome digital charge-coupled device (CCD) camera (F-View II;
Olympus Soft Imaging Solutions). To observe the tumors with high magnifica-
tion, liver, femurs, and tibias were resected from transparentized mice
and observed using a confocal microscopy (FV-1000; Olympus). Images
were acquired using a 303 silicone immersion objective lens (NA 1.05). 3D
reconstruction was performed from z stack images using Volocity software
(PerkinElmer).632 Cell Reports 12, 622–635, July 28, 2015 ª2015 The AuthorsReagents
Ulocuplumab and the control human IgG4 isotype control were obtained from
Bristol-Myers Squibb. Bortezomib and lenalidomide were obtained from Sell-
eck Chemicals.
Immunohistochemistry and Immunofluorescence
Autopsy specimens of synchronous secondary extramedullary MM sites were
analyzed for the expression of CD138 and CXCR4. Murine BM tissues (femurs)
were analyzed for the expression of human CD138 and stained with hema-
toxylin-eosin. Imageswere takenusingNikonEclipse80imicroscope (objectives
203 and 1003). Immunofluorescence imagingwas performed on CXCR4-over-
expressing MM cells for evaluating actin cytoskeleton reorganization, using a
confocal microscope (Nikon TE2000-E; objectives 403 and 1003). DAPI was
used as nuclear staining. Anti-actin Alexa Fluor 594 conjugated was used (Cell
Signaling). Images were taken using the Hamamatsu OrcaER camera and the
NIS-Element software. Image J was used to merge the two different channels.
Immunoblotting
Cells were harvested and lysed using lysis buffer (Cell Signaling Technology)
supplementedwith 5mMNaF, 2mMNa3VO4, 1mMPMSF (polymethylsulfonyl
fluoride), 5 mg/ml leupeptin, and 5 mg/ml aprotinin. Whole-cell lysates were
subjected to SDS-PAGE and transferred to polyvinylidene fluoride (PVDF)
membrane (Bio-Rad). The antibodies used for immunoblotting included anti-
CXCR4, -E-cadherin, -N-cadherin, -Slug, -Snail, -Twist, phosphor (p)-ERK,
-p-Akt, -p-paxillin, -p-Src, p-b-catenin, -b-catenin, -p-GSK3-b, -caspase-9,
-PARP, -GAPDH, -tubulin, and -actin antibodies (Cell Signal). Protein band
quantification was obtained using Image J, as previously described (Kovaleva
et al., 2012).
In Vitro Studies
DNA synthesis was measured by [3H]-thymidine ([3H]-TdR; PerkinElmer) up-
take, or MTS, as previously described (Roccaro et al., 2010; Sacco et al.,
2011). Cell toxicity has been evaluated by measuring 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT; Chemicon International), as
described (Azab et al., 2012b; Roccaro et al., 2010; Sacco et al., 2011). Inva-
sion assay was assessed using a Matrigel invasion chamber assay (Corning).
Cell migration was determined using the transwell migration assay (Costar), as
previously described (Azab et al., 2012a).
In Vivo Studies
Intravital confocal microscopy was performed as previously reported (Col-
mone et al., 2008; Roccaro et al., 2013) using a Zeiss 710 confocal system
(Carl Zeiss) on an upright Examiner stand with a custom stage. Briefly, a
skin flap was made in the scalp of the mice to expose the underlying dorsal
skull surface. High-resolution images with cellular detail were obtained
through the intact mouse skull at depths of up to 250 mm from the surface of
the skull using a 103 0.45NA Plan-Apo objective (Carl Zeiss) and assembled
together to generate a final image that depicts the whole bone marrow. Multi-
ple imaging depths were acquired, and a maximum intensity z projection was
performed to merge the images. GFP was excited with the 488 nm line on an
argon laser. Blood vessels were imaged using Evans Blue (Sigma-Aldrich)
excited with a 633 nm laser. Emission signals were collected by using the Zeiss
internal confocal Quasar detectors.
In vivo tumor growth has been assessed by using in vivo bioluminescence
imaging. Mice were injected with 75 mg/kg of Luciferin (Xenogen), and tumor
growth was detected by bioluminescence 3min after the injection, using Xeno-
gen In Vivo Imaging System (Caliper Life Sciences), as previously reported
(Roccaro et al., 2009). The in vivo MM metastasis model was performed, as
previously reported (Roccaro et al., 2014). Briefly, bone chips were loaded
with human (GFP+ MM.1S) MM cells (23 106 cells/bone). Two bones were im-
planted subcutaneously into SCID/Bg mice (n = 5/group). Mice received either
isotype control antibody or ulocuplumab (intra-peritoneal [i.p.]; 10 mg/kg; 33
to 43/week). Mice were euthanized once signs or limb paralysis were evident.
MM cells have been harvested from one host femur and evaluated by flow cy-
tometry for GFP/human CD138 positivity. The remaining host femur has been
used for immunohistochemistry using human anti-CD138 for detecting metas-
tasized MM.1S cells. Six-week-old female SCID-beige mice (Taconic) were
treated, monitored, and sacrificed in accordance with approved protocol of
the Dana-Farber Cancer Institute Animal Care and Use Committee.
MM Xenograft s.q. Models
SCID mice were subcutaneously implanted with 10 million RPMI-8226,
MM.1S, or OPM-2 cells in 0.1 ml PBS and 0.1 ml Matrigel, as previously
described (Zhang et al., 2014). One day prior to dosing, mice were randomized
into groups of eight mice each according to tumor volume (L3W3H/2). Post-
implantation, mice were dosed with ulocuplumab (10 mg/kg; 33 to 43/week;
i.p.), human IgG4 isotype (30 mg/kg; 33 to 43/week; i.p.), bortezomib
(0.8 mg/kg; 23/week; i.p.), or Revlimid (50 mg/kg; daily; i.p.). Tumors and
body weights were measured twice weekly. Tumors were measured in three
dimensions with a Fowler Electronic Digital Caliper (model 62379-531;
Fred V. Fowler), and data were electronically recorded using StudyDirector
software from Studylog Systems. Animals were checked daily for postural,
grooming, and respiratory changes, as well as lethargy. Mice were euthanized
when the tumors reached the 2,000 mm3 endpoint or appeared ulcerated.
All antibody doses were well tolerated, and no body weight losses were
observed.
CXCR4 Gain and Loss of Function
CXCR4 was silenced in MM.1S cells using shRNAs and lentivirus-medi-
ated infection; scramble probe has been used as control (G9 clone;
TRCN0000256866; Broad Institute RNAi Consortium), according to manufac-
turer’s specifications. Transduction efficiency was performed by using qRT-
PCR and western blot (Livak and Schmittgen, 2001). Overexpression of
CXCR4 was obtained in MM.1S and RPMI.8226 cells using precision
LentiORF/CXCR4 (CXCR4+) or EV used as control (Thermo Scientific). Overex-
pression efficiency was performed by using qRT-PCR and western blot (Livak
and Schmittgen, 2001).
mRNA Studies
We utilized a public MM gene expression data set GSE24080 to explore the
pathways potentially regulated by CXCR4. We ranked all 577 MM samples
by their normalized CXCR4 expression levels and compared gene expression
between top 100 samples with highest CXCR4 expression and top 100 sam-
ples with lowest CXCR4 expression. Gene set enrichment analysis (GSEA)
was used to identify significantly enriched pathways (Subramanian et al.,
2005). Gene sets were downloaded from the Broad Institute’s MSigDB
(http://www.broadinstitute.org/gsea/index.jsp).
RNA Sequencing Analysis
Total RNA was isolated from EMD-prone and BM-prone cell lines using
RNeasy Mini kit (QIAGEN). During isolation step, RNA was treated with
DNase I according to the manufacturer’s protocol. For RNA sequencing,
poly-A selection and cDNA synthesis were performed, followed by library
preparation using Illumina TruSeq RNA Sample Prep Kit, sequencing (75-bp
paired reads), and sample identification for quality control. We used Bcbio_
nextgen (https://github.com/chapmanb/bcbio-nextgen/) to process the
RNA-seq data. Briefly, cutadapt (https://github.com/marcelm/cutadapt/)
was used to trim adapters, trimmed reads were aligned to human reference
genome (GRCh37) with tophat2 (Kim et al., 2013), and read count for each
gene was calculated by HT-seq (Anders et al., 2015). Genes with low expres-
sion (FPKM < 1 across all samples) were filtered out. GSEA was used to iden-
tify differentially expressedmRNA signatures, with false discovery rate (FDR) <
0.25 and p value < 0.05.
Statistics
The p values described in the in vitro assays are based on t tests (two-tailed;
a 0.05). p values are provided for each figure. The average of experiments per-
formed in triplicate is shown. The Kaplan-Meier curve was obtained using
GraphPad Prism, and the p value was calculated based on log rank test.
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